

FOR IMMEDIATE RELEASE

Media Contact:
National Infusion Center Association
advocacy@infusioncenter.org

NICA Warns Medicare Drug Price Negotiation Could Threaten Community Infusion Access

Organization urges Congress to pass PACTA and calls on providers to make their voices heard

AUSTIN, Texas, August –, 2026 — The National Infusion Center Association (NICA) is urging Congress to pass H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act (PACTA), before Medicare's first negotiated prices for Part B drugs take effect in 2028.

The Medicare Drug Price Negotiation Program is intended to lower costs for Medicare and patients. But for selected Part B drugs, the law also changes provider reimbursement from the Average Sales Price plus 6% to the negotiated Maximum Fair Price plus 6%, which would establish an untenable cut in providers' reimbursement for negotiated drugs. Because infusion providers rely on their drugs payment to help cover the costs and financial risks of acquiring, storing, handling, and administering complex therapies, the change could make it financially unsustainable for some community practices to continue offering selected treatments.

"Congress intended for the Medicare drug price negotiation program to lower costs for Medicare and patients, but as currently structured it risks making it harder for patients to receive treatment in their own communities," said Brian Nyquist, Chief Executive Officer of the National Infusion Center Association. "PACTA preserves the intent of the negotiation program while protecting the providers who make access to these therapies possible. Congress needs to act before this payment change disrupts patient care."

PACTA would preserve ASP-based provider reimbursement and require manufacturers to pay Medicare a rebate reflecting the difference between the ASP-based and negotiated-price amounts. Medicare would retain the negotiated savings, and patient cost-sharing would remain based on the lower Maximum Fair Price.

NICA is also calling on infusion providers to contact their members of Congress and explain what the payment change could mean for practices and patients in their communities. More than 250 providers have already signed state letters supporting PACTA.

“Lawmakers need to hear directly from providers in their states and districts,” Nyquist said. “If Congress does not hear from the people who furnish these treatments, lawmakers may not understand what is at stake until patients begin losing access. Providers cannot wait for that to happen.”

Authorized practice representatives in California, Illinois, Nevada, New Jersey, New York, Pennsylvania, and Texas can [sign the PACTA provider letter](#) through Friday, August 28, 2026. Providers nationwide can use [NICA's grassroots advocacy platform](#) to contact their lawmakers.

About the National Infusion Center Association

The National Infusion Center Association (NICA) is a nonprofit trade association representing community-based infusion providers and the patients they serve. NICA works to protect and expand access to provider-administered medications through education, provider support, and advocacy. Learn more at infusioncenter.org.